Demand for schizophrenia treatment will increase through 2036, with atypical antipsychotic drugs at 51.2% of the product type segment in 2026, driven by high adoption across primary application categories. The market was valued at USD 11.20 billion in 2025 and is expected to be worth USD 24.56 billion by 2036.